Immuneering Corporation reported that their drug atebimetinib combined with anti-PD-1 immunotherapy cured 50% of mice in a RAS-mutant colorectal cancer model and nearly doubled median survival in a RAS-mutant lung cancer model. The combination also reversed immune suppression and enhanced anti-tumor activity in preclinical studies. Encouraged by these results, Immuneering plans to start a Phase 2 clinical trial by year-end testing atebimetinib with anti-PD-1 and chemotherapy in first-line RAS-mutant non-small cell lung cancer patients. This development could lead to improved treatment options for cancers driven by RAS mutations.
The story on atebimetinib combinations with anti-PD1 immunotherapy is presented with Pluang's health sector market data as of Nov 06, 2026 20:42 WIB. Of 150 priced health-sector US stocks tradable on Pluang, 51 rose and 94 fell today. Notable movers include TXG at USD 55.94 with a -3.65% change and 88% sell order activity, HRTX at USD 0.29 with a +3.54% change and 76% buy order activity, and SNN at USD 30.91 with a -3.44% change. The most notable figure is the 88% sell order activity for TXG.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
